{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:58:25Z","timestamp":1771005505608,"version":"3.50.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1996,10,1]],"date-time":"1996-10-01T00:00:00Z","timestamp":844128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[1996,10]]},"DOI":"10.1007\/bf00820726","type":"journal-article","created":{"date-parts":[[2004,12,15]],"date-time":"2004-12-15T12:41:40Z","timestamp":1103114500000},"page":"153-162","source":"Crossref","is-referenced-by-count":37,"title":["Advanced and controlled drug delivery systems in clinical disease management"],"prefix":"10.1007","volume":"18","author":[{"given":"J. R. B. J.","family":"Brouwers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","unstructured":"Montague MJ. Biotechnology CE Series: Biotechnology and the future of medicine. Pharm Pract News 1993 (jan.); p3:p13:p31."},{"issue":"suppl. 1","key":"CR2","first-page":"186","volume":"44","author":"SS Davis","year":"1992","unstructured":"DavisSS. Delivery for biopharmaceuticals. J Pharm Pharmacol 1992: 44 (suppl. 1):186?90.","journal-title":"J Pharm Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00000441-199201000-00008","volume":"303","author":"JD Morrow","year":"1992","unstructured":"MorrowJD. The oral cephalosporins: a review. Am J Med Sci 1992;303:35?9.","journal-title":"Am J Med Sci"},{"key":"CR4","first-page":"39","volume":"33","author":"C Beglinger","year":"1993","unstructured":"BeglingerC, DreweJ, KisselT. The absorption site of cyclosporin in human gastro-intestinal tract. Br J Clin Pharmacol 1993; 33: 39?43.","journal-title":"Br J Clin Pharmacol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2125.1995.tb05722.x","volume":"39","author":"AK Trull","year":"1995","unstructured":"TrullAK, TanKK, TanL, AlexanderGJ, JamiesonNV. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Brit J Clin Pharmacol 1995;39:627?31.","journal-title":"Brit J Clin Pharmacol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0169-409X(95)00002-O","volume":"15","author":"WM Pardridge","year":"1995","unstructured":"PardridgeWM. Preface: overview of brain drug delivery. Adv Drug Deliv Rev 1995; 15: 1?3.","journal-title":"Adv Drug Deliv Rev"},{"key":"CR7","first-page":"274","volume":"29","author":"EM Delhaas","year":"1991","unstructured":"DelhaasEM, BrouwersJRBJ. Intrathecal baclofen overdose: report of 7 events in 5 patients and review of literature. Int J Clin Pharmacol Ther Tox 1991; 29: 274?80.","journal-title":"Int J Clin Pharmacol Ther Tox"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1001\/jama.1993.03510200081036","volume":"270","author":"AL Albright","year":"1993","unstructured":"AlbrightAL, BarronWB, FasickMP, PolinkoP, JanoskyJ. Continuous intratecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 2475?7.","journal-title":"JAMA"},{"key":"CR9","first-page":"340","volume-title":"Progress in Clinical Pharmacy","author":"JRBJ Brouwers","year":"1990","unstructured":"BrouwersJRBJ, CramerK, GulyasJ, Van derKamHJ, SijtsmaJ. Intraportal 5-FU for colorectal hepatic metastasis and adjuvant treatment: a tolerance dose study in: ?Progress in Clinical Pharmacy? editors NFMuller & YAHekster. Eur Soc Clin Pharm, Amsterdam Medical Press, Noordwijkerhout 1990; 340?42."},{"key":"CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(95)90340-2","volume":"345","author":"Swiss Group for Clinical Cancer Research (SAKK)","year":"1995","unstructured":"Swiss Group for Clinical Cancer Research (SAKK). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995; 345: 349?53.","journal-title":"Lancet"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01962681","volume":"10","author":"CHW Koks","year":"1988","unstructured":"KoksCHW, BrouwersJRBJ, SleijfferDTh. Regional infusion of fluoropyrimidines for hepatic metastasis of colorectal cancer. Pharm Weekbl [Sci] 1988; 10: 69?75.","journal-title":"Pharm Weekbl [Sci]"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/1097-0142(19940215)73:4<1134::AID-CNCR2820730403>3.0.CO;2-V","volume":"73","author":"N Kemeny","year":"1994","unstructured":"KemenyN, SeiterK, ContiJA, CohenA, BertinoJR, SigurdsonER, et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastasis for colorectal carcinoma. Cancer 1994; 73; 1134?42.","journal-title":"Cancer"},{"key":"CR13","unstructured":"Braat DDM. Multiple pregnancies in pulsatile GnRH treatment. Thesis Free University of Amsterdam, Amsterdam 1992."},{"key":"CR14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/bdd.2510110602","volume":"11","author":"A Rubinstein","year":"1990","unstructured":"RubinsteinA. Microbially controlled drug delivery to the colon. Biopharm Drug Disp 1990; 11: 465?75.","journal-title":"Biopharm Drug Disp"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF02660618","volume":"3","author":"I Bjarnason","year":"1993","unstructured":"BjarnasonI, McPhersonAJ. Delivery, safety and efficacy of 5-aminosalicylate preparations. Inflammopharmacol 1993; 3: 277?87.","journal-title":"Inflammopharmacol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/gut.35.9.1155","volume":"35","author":"G Jarnerot","year":"1994","unstructured":"JarnerotG. New salicylates as maintenance treatment in ulcerative colitis. Gut 1994; 35: 1155?8.","journal-title":"Gut"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2036.1994.tb00290.x","volume":"8","author":"LA Christensen","year":"1994","unstructured":"ChristensenLA, FallingborgJ, JacobsenBA, AbildgaardK, RasmussenHH, HansenSH, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled-release preparation and azo-bound preparation. Alim Pharmacol Ther 1994; 8: 289?94.","journal-title":"Alim Pharmacol Ther"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02660620","volume":"2","author":"RP Metha","year":"1993","unstructured":"MethaRP. Nephropathy from 5-aminosalicylate preparations. Inflammopharmacol 1993; 2: 297?300.","journal-title":"Inflammopharmacol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/gut.35.10.1493","volume":"35","author":"PJ Thuluvath","year":"1994","unstructured":"ThuluvathPJ, NincovicM, CalamJ, AndersonM. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493?6.","journal-title":"Gut"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00054725-199506000-00006","volume":"1","author":"R L\u00f6fberg","year":"1995","unstructured":"L\u00f6fbergR. New steroids for inflammatory bowel disease. Inflam Bowel Dis 1995; 1: 135?41.","journal-title":"Inflam Bowel Dis"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2036.1993.tb00080.x","volume":"7","author":"CJJ Mulder","year":"1993","unstructured":"MulderCJJ, TytgatGNJ. Review article: topical corticosteroids in inilammatory bowel disease. Alim Pharmacol Therap 1993; 7: 125?30.","journal-title":"Alim Pharmacol Therap"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-2007-1007278","volume":"15","author":"DDM Meller","year":"1995","unstructured":"MellerDDM, MolemaG. Targeting of drug to the liver. Sem Liver Dis 1995; 15:202?56.","journal-title":"Sem Liver Dis"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/875512259200800509","volume":"8","author":"DE Hilleman","year":"1992","unstructured":"HillemanDE, BanakarUV. Issue in contemporary drug delivery, Part VI: Advanced cardiac drug formulations. J Pharm Techn 1992; 8: 203?11.","journal-title":"J Pharm Techn"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0002-9149(99)80104-0","volume":"76","author":"WB White","year":"1995","unstructured":"WhiteWB, AndersRJ, McIntyreJM, BlackHR, SicaDA and the Verapamil Study Group. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol 1995; 76: 375?80.","journal-title":"Am J Cardiol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.2510150104","volume":"15","author":"M Badler","year":"1994","unstructured":"BadlerM, HadadS, GolombG, BarelS, SamaraE, SalachOA, et al. Pharmacokinetic analysis of two new sustained release products of dilthiazem designed for twice and once daily treatment. Biopharm Drug Disp 1994; 15: 45?52.","journal-title":"Biopharm Drug Disp"},{"issue":"Suppl 5","key":"CR26","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/00005344-199423005-00006","volume":"23","author":"PA Meredith","year":"1994","unstructured":"MeredithPA, ElliottHL. FDA guidelines on through:peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration. J Cardiovasc Pharmacol 1994; 23 (Suppl 5) S26?30.","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR27","first-page":"49","volume-title":"Orale toedienings vormen met gereguleerde afgiften","author":"JRBJ Brouwers","year":"1989","unstructured":"BrouwersJRBJ. Orale toedienings vormen met gereguleerde afgiften. Stichting Anselmus, Heesch, The Netherlands 1989; 49?58."},{"key":"CR28","first-page":"49","volume":"41","author":"N Hagen","year":"1995","unstructured":"HagenN, FlynneP, HagsH, Mac DonaldN. Guidelines for managing chronic non-malignant pain: opioid and other agents. Can Family Physician 1995; 41: 49?53.","journal-title":"Can Family Physician"},{"key":"CR29","first-page":"91","volume":"149","author":"EM Delhaas","year":"1989","unstructured":"DelhaasEM, BrouwersJRBJ. The spinal and epidural administration of narcotic analgesics in cancer patients. Royal Soc Med 1989 Congres Series nr 149: 91?3.","journal-title":"Congres Series nr"},{"issue":"Suppl 1","key":"CR30","first-page":"139","volume":"74","author":"P LeCorre","year":"1995","unstructured":"LeCorreP, PolardE, ChevannetF, LeVergeR. Morphine-controlled release from microspheres for site-specific delivery (abstract 456). Brit J Anesth 1995; 74 (Suppl 1): 139.","journal-title":"Brit J Anesth"},{"issue":"Suppl 1","key":"CR31","first-page":"139","volume":"75","author":"U Oral","year":"1995","unstructured":"OralU, IsikG, OzbekH, G\u00fclerI. Intranasal fentanyl administration for postoperative pain (Abstract 458). Intranasal alfentaryl administration for postoperative pain (A459). Brit J Anaesth 1995; 75 (Suppl 1): 139.","journal-title":"Brit J Anaesth"},{"key":"CR32","first-page":"140","volume":"74","author":"PK Wong","year":"1995","unstructured":"WongPK, AsburgAJ, WardKM, DonellD, WrayH, StamponeP et al. Fentanyl by metered dose breath-actuated inhaler as analgesic after total abdominal hysterectomy. A clinical evaluation (Abstract 460). Brit J Anes 1995; 74: 140.","journal-title":"Brit J Anes"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/104990918900600409","volume":"6","author":"CM Maloney","year":"1989","unstructured":"MaloneyCM, KesnerRK, KlemG, BockenstetteJ. The rectal administration of MS-Contin: clinical implications for use in end-stage cancer. Am J Hospice Palliative Care 1989; 6: 34?5.","journal-title":"Am J Hospice Palliative Care"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF01954551","volume":"6","author":"F Moolenaar","year":"1984","unstructured":"MoolenaarF, FietsG, VisserJ, MejjerDKF. Prelimary study on the absorption profile after rectal and oral administration of methadone in human volunteers. Pharm Weekbl [Sci] 1984; 6: 237?40.","journal-title":"Pharm Weekbl [Sci]"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/bja\/61.2.221","volume":"61","author":"CD Hamming","year":"1988","unstructured":"HammingCD, VickersAP, SmithG, GrahamNB, McNeilME. The morphine hydrogel suppository: a new sustained-release rectal preparation. Brit J Anesth 1988; 61: 221?7.","journal-title":"Brit J Anesth"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/JCO.1995.13.4.1004","volume":"13","author":"F Conno","year":"1995","unstructured":"ConnoF, RipamontiC, SaitiL, MacEachernT, HansonJ, BrueraE. Role of rectal route in treating cancer pain: a randomized cross-over clinical trail of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13: 1004?8.","journal-title":"J Clin Oncol"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0196-0644(94)70234-9","volume":"24","author":"SA Schulzman","year":"1984","unstructured":"SchulzmanSA. Oral transmucosal fentanyl citrate for premedication of children undergoining laceration repair. Ann Emerg Med 1984; 24:1059?64.","journal-title":"Ann Emerg Med"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1524-4725.1994.tb03712.x","volume":"201","author":"JW Gerwels","year":"1994","unstructured":"GerwelsJW. Oral transmucosal fentanyl citrate premedication in patients undergoining outpatient dermatologic procedures. J Dermatol Surg Oncol 1994; 201:823?26.","journal-title":"J Dermatol Surg Oncol"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/bja\/75.3.260","volume":"75","author":"L Duncan","year":"1995","unstructured":"DuncanL, WildsmithJAW. Liposomal local anaesthetics (Editorial). Brit J Anaesth 1995; 75: 260?1.","journal-title":"Brit J Anaesth"},{"key":"CR40","first-page":"373","volume-title":"therapeutic applications of NSAIDs: subpopulations and new formulations","author":"I Vavra","year":"1992","unstructured":"VavraI, PaulusHE. Controlled-release and enteric-coated formulations of NSAIDs. In. therapeutic applications of NSAIDs: subpopulations and new formulations. Editor: J.P.Famaey & H.E.Paulus. Marcel Dekker Inc. New York 1992; p. 373?83."},{"key":"CR41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0002-9343(94)90153-8","volume":"96","author":"D Hollander","year":"1994","unstructured":"HollanderD. Gastro-intestinal complications of NSAIDs: prophylactic and therapeutic strategies. Am J Med 1994; 96: 274?81.","journal-title":"Am J Med"},{"key":"CR42","first-page":"94","volume":"11","author":"R Janknegt","year":"1995","unstructured":"JanknegtR, BrouwersJRBJ, VanRielPLCM. Drug evaluation for non steroidal anti-inflammatory drugs by the SOJA method (Dutch). Ziekenhuisfarmacie (Neth.) 1995; 11: 94?106.","journal-title":"Ziekenhuisfarmacie (Neth.)"},{"key":"CR43","doi-asserted-by":"crossref","unstructured":"Anonymous. Drugs for Parkinson's disease reviewed. Drug Ther Bull 1995; 33: 49?52.","DOI":"10.1136\/dtb.1995.33749"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","volume":"47","author":"JM Davis","year":"1994","unstructured":"DavisJM, MetalonL, WanatabeMD, BlakeL. Depot antipsychotic drugs place in therapy. Drugs 1994; 47:741?773.","journal-title":"Drugs"},{"key":"CR45","unstructured":"WHO. Mechanism of action, safety and efficacy of intrauterine devices. WHO Tech Rep Ser no. 753, 1987."},{"key":"CR46","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1471-0528.1993.tb15271.x","volume":"100","author":"T Naessen","year":"1993","unstructured":"NaessenT, PerssonI, ThorL, MallminH, LjunghallS, Berstrom. Maintained bone density at advanced ages after longterm treatment with low dose oestradiol implants. Brit J Obstet Gynaecol 1993; 100:454?9.","journal-title":"Brit J Obstet Gynaecol"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/24.3.277","volume":"24","author":"PJ Sanderson","year":"1989","unstructured":"SandersonPJ. Leading Article: Preventing infections orthopaedic implants. J Antimicrob Chemoth 1989; 24: 277?80.","journal-title":"J Antimicrob Chemoth"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jor.1100120110","volume":"12","author":"Fr DiMaio","year":"1994","unstructured":"DiMaioFr, HalloranJJ, QualeJM. In vitro elution of ciprofloxacin from polymethylmethacrylate beads. Orth Res 1994; 12: 79?82.","journal-title":"Orth Res"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00003086-199311000-00040","volume":"296","author":"PW Brien","year":"1993","unstructured":"BrienPW, SalvataEA, KleinR, BrauseB, SternS. Antibiotic impregnated bone cement in total hip arthroplasty. An in vivo comparison of the elution properties of tobramycin and vancomycin. Clin Orthop 1993; 296: 242?8.","journal-title":"Clin Orthop"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jor.1100110212","volume":"11","author":"TN Gerhart","year":"1993","unstructured":"GerhartTN, RouxPD, HanffPA, HorowitzGL, RenshawAA, HayesWC. Antibiotic loaded biodegradable bone cement for prophylaxis and treatment of experimental osteomylitis. Orthop Res 1993; 11: 250?5.","journal-title":"Orthop Res"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0950-821X(05)80933-8","volume":"5","author":"LG J\u00f6rgensen","year":"1991","unstructured":"J\u00f6rgensenLG. Clinical and pharmacokinetic evaluation of gentamicin containing collagen in groin wound infections. Eur J Vasc Surg 1991; 5: 87?91.","journal-title":"Eur J Vasc Surg"},{"key":"CR52","first-page":"459","volume":"93","author":"C Hasselbach von","year":"1989","unstructured":"HasselbachvonC. Klinik und Pharmakokinetiek von Kollagen-Gentamicin als adjuvante Lokal therapie kn\u00f6cherner Infektion. Unfallchirung 1989; 93: 459?70.","journal-title":"Unfallchirung"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0039-6109(16)46330-9","volume":"74","author":"DF Bandijk","year":"1994","unstructured":"BandijkDF, EssesGE. Prosthetic graft infection. Surg Clin Nort Am 1994; 74: 571?90.","journal-title":"Surg Clin Nort Am"},{"key":"CR54","first-page":"92","volume":"2","author":"TM Bergamini","year":"1994","unstructured":"BergaminiTM, McCurryTM, BernardJD, HoegKL, CorpusRA, PeytonJC, et al. Antibiotic efficacy against staphylococcus epidermidis adherent to vascular grafts. Vasc Forum 1994; 2: 92?3.","journal-title":"Vasc Forum"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0741-5214(94)70050-8","volume":"19","author":"O Go\u00ebau-Brissonni\u00e8re","year":"1994","unstructured":"Go\u00ebau-Brissonni\u00e8reO, MercierF, NicolasMH, BacourtF, CoggiaM, LebrautC, et al. Treatment of vascular graft infection by in situ replacement with a rifampicin-bonded gelatin-sealed Dacron graft. J Vasc Surg 1994; 19: 739?44.","journal-title":"J Vasc Surg"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/CMR.6.2.176","volume":"6","author":"DA Goldmann","year":"1993","unstructured":"GoldmannDA, PieGB. Pathogenesis of infections related to intravascular catheterisation. Clin Microbiol Rev 1993; 6: 176?92.","journal-title":"Clin Microbiol Rev"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0140-6736(95)90097-7","volume":"345","author":"P Appelgren","year":"1995","unstructured":"AppelgrenP, Ransj\u00f6U, BindslevL, LarmO. Does surface heparinisation reduce bacterial colonisation of central venous catheters? Lancet 1995; 345: 130 (letter).","journal-title":"Lancet"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01982182","volume":"13","author":"SE Tebbs","year":"1994","unstructured":"TebbsSE, ElliotTSJ. Modification onf central venous catheter polymers to prevent in vitro microbial colonisation. Eur J Clin Microbiol Infect Dis 1994; 13: 111?7.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1128\/AAC.39.11.2397","volume":"39","author":"I Raad","year":"1995","unstructured":"RaadI, DarouicheR, HachenR, SacilowskiM, BodeyGP. Antibiotics and prevention of microbial colonisation of catheters. Antimicrob Agents Chemother 1995; 39: 2397?2400.","journal-title":"Antimicrob Agents Chemother"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0169-409X(95)00014-X","volume":"16","author":"MF Saettone","year":"1995","unstructured":"SaettoneMF, SalminenL. Ocular inserts for topical delivery. Adv Drug Deliv Rev 1995; 16: 95?106.","journal-title":"Adv Drug Deliv Rev"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0169-409X(95)00017-2","volume":"16","author":"A Zimmer","year":"1995","unstructured":"ZimmerA, KreuterJ. Microspheres and nanoparticles used in ocular delivery systems. Advanced Drug Deliv Rev 1995; 16: 61?73.","journal-title":"Advanced Drug Deliv Rev"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0169-409X(95)00016-Z","volume":"16","author":"D Meisner","year":"1995","unstructured":"MeisnerD, MezeiM. Liposome ocular delivery systems. Advanced Drug Deliv Rev 1995; 16: 75?93.","journal-title":"Advanced Drug Deliv Rev"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(95)91681-4","volume":"346","author":"JT Ernest","year":"1995","unstructured":"ErnestJT. Intraocular device for cytomegalovirus infection. Lancet 1995; 346: 983?4.","journal-title":"Lancet"},{"key":"CR64","first-page":"1","volume":"17","author":"JJ Bergers","year":"1995","unstructured":"BergersJJ, tenHagenTLM, vanEttenEWM, Bakker-WoudenbergIAJM. Liposomes as delivery systems in the prevention and treatment of infectious diseases. PWS 1995; 17: 1?11.","journal-title":"PWS"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jac\/33.5.907","volume":"33","author":"S Marie De","year":"1994","unstructured":"DeMarieS, JanknegtR, Bakker-WoudenbergIAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907?16.","journal-title":"J Antimicrob Chemother"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00002018-199513040-00001","volume":"13","author":"J Tollenaar","year":"1995","unstructured":"TollenaarJ, RingdenO. Lipid formulation of amphotericin B less toxicity but at what economic cost? Drug Safety 1995; 13: 207?18.","journal-title":"Drug Safety"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00003246-199501000-00016","volume":"23","author":"LS Grayson","year":"1995","unstructured":"GraysonLS, HansbroughJF, Zapata-SirventR, RoehrbornAJ, KimT, KimS. Soft tissue infection prophylaxis with gentamicin encapsulated in multi-vascular liposomes: results from a prospective, randomized trial. Crit Care Med 1995; 23: 84?91.","journal-title":"Crit Care Med"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1128\/AAC.39.9.1973","volume":"39","author":"RF Omar","year":"1995","unstructured":"OmarRF, DussereN, D\u00e9sormeauxA, PoulesL, TremblayM, BeauchampD, et al. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob Agents Chemother 1995; 39: 1973?8.","journal-title":"Antimicrob Agents Chemother"},{"key":"CR69","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2165\/00003495-199346040-00004","volume":"46","author":"S Kim","year":"1993","unstructured":"KimS. Liposomes as carriers of cancer chemotherapy: current status and future prospects. Drugs 1993; 46: 618?38.","journal-title":"Drugs"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.1995.13.4.996","volume":"13","author":"PS Gill","year":"1995","unstructured":"GillPS, EspinaBM, MuggiaF, CabrialisS, TulpuleA, EsplinJA et al. Phase I\/II clinical and phartmacokinetic evaluation of liposomal daunorubicin. J. Clin Oncol 1995; 13:996?1003.","journal-title":"J. Clin Oncol"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/0140-6736(93)91147-E","volume":"341","author":"CA Presant","year":"1993","unstructured":"PresantCA, ScolaroM, KennedyP, BlayneyDW, FlanagenB, LisakJ, et al. Liposomal daunorubicin treatment of HIV associated Kaposi's sarcoma. Lancet 1993; 341: 1242?43.","journal-title":"Lancet"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","volume":"345","author":"H Brem","year":"1995","unstructured":"BremH, PlantadosiS, BurgerPC, WalkerM, SelkerR, VickNA, et al. Placebo-controlled trial of safety and efficacy of intra operative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345: 1008?12.","journal-title":"Lancet"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/1097-0142(19940801)74:3+<1006::AID-CNCR2820741506>3.0.CO;2-V","volume":"74","author":"CB Siegall","year":"1994","unstructured":"SiegallCB. Targeted toxins as anticancer agents. Cancer 1994; 74: 1006?12.","journal-title":"Cancer"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00003495-199142020-00004","volume":"42","author":"FP Kennedy","year":"1991","unstructured":"KennedyFP. Recent developments in insulin delivery techniques: current status and future potential. Drugs 1991; 42: 213?27.","journal-title":"Drugs"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0001-2998(05)80226-0","volume":"24","author":"AM Peters","year":"1994","unstructured":"PetersAM. The utility of99mTc-HMPAO-leukocytes for imaging infection. Sem Nucl Med 1994; 24: 110?27.","journal-title":"Sem Nucl Med"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0001-2998(05)80225-9","volume":"24","author":"FL Datz","year":"1994","unstructured":"DatzFL. Indium-111-labeled leukocytes for the detection of infection: current status. Sem Nucl Med 1994; 24: 92?109.","journal-title":"Sem Nucl Med"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0001-2998(05)80230-2","volume":"24","author":"RH Rubin","year":"1994","unstructured":"RubinRH, FischmanA. The use of radiolabeled nonspecific immunoglobulin in the detection of focal inflammation. Sem Nucl Med 1994; 24: 169?79.","journal-title":"Sem Nucl Med"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0001-2998(05)80229-6","volume":"24","author":"AJ Fischman","year":"1994","unstructured":"FischmanAJ, BabichJW, RubinRH. Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Sem Nucl Med 1994; 24: 154?168.","journal-title":"Sem Nucl Med"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0001-2998(05)80022-4","volume":"24","author":"GB Saha","year":"1994","unstructured":"SahaGB, MclntyreWJ, GoRT. Radiopharmaceuticals for brain imaging. Sem Nucl Med 1994; 24: 324?49.","journal-title":"Sem Nucl Med"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/bmj.305.6865.1348","volume":"305","author":"RE Hawkins","year":"1993","unstructured":"HawkinsRE, LewelynMB, RusselSJ. Adapting antibodies for clinical use. Brit Med J 1993; 305: 1348?52.","journal-title":"Brit Med J"},{"key":"CR81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00002018-199512010-00006","volume":"12","author":"NA Buckley","year":"1994","unstructured":"BuckleyNA, DawsonAH, ReithDA. Controlled-release of drugs in overdose. Drug Saf 1994; 12: 73?84.","journal-title":"Drug Saf"},{"key":"CR82","doi-asserted-by":"crossref","unstructured":"Anonymous. Controlled release formulations delay and prolong linical effects following overdose. Drugs Ther Persp 1995; 5 (7): 11?13.","DOI":"10.2165\/00042310-199505070-00005"},{"issue":"Suppl 1","key":"CR83","first-page":"186","volume":"44","author":"SS Davis","year":"1992","unstructured":"DavisSS. Delivery systems for biopharmaceuticals. J Pharm Pharmacol 1992; 44 (Suppl 1): 186?90.","journal-title":"J Pharm Pharmacol"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.1993.03500020083037","volume":"269","author":"DB Chalfin","year":"1993","unstructured":"ChalfinDB, HolbeinMEB, FeinAM, CarlonGC. Cost-effectiveness of monoclonal antibodies to Gram-negative endotoxin in the treatment of Gram-negative sepsis in ICU patients. JAMA 1993; 269: 249?54.","journal-title":"JAMA"},{"key":"CR85","doi-asserted-by":"crossref","first-page":"S 436","DOI":"10.1097\/00003246-199310001-00004","volume":"241","author":"JC Wherry","year":"1993","unstructured":"WherryJC, PenningtonJE, WenzelRP. Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 1993; 241: S 436?440.","journal-title":"Crit Care Med"},{"key":"CR86","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0140-6736(93)93139-R","volume":"341","author":"JC Hurley","year":"1993","unstructured":"HurleyJC. Reappraisal of the role of endotoxin in the sepsis syndrome. Lancet 1993; 341: 1133?5.","journal-title":"Lancet"},{"key":"CR87","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/00003246-199311000-00006","volume":"21","author":"EA Deitch","year":"1993","unstructured":"DeitchEA. Cytokines yes, cytokines no, cytokinesmay be. Crit Care Med 1993; 21: 817?19.","journal-title":"Crit Care Med"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJM199511023331808","volume":"333","author":"HM Blau","year":"1995","unstructured":"BlauHM, SpringerML. Gene therapy a novel form of drug delivery. New Engl J Med 1995; 333: 1204?7.","journal-title":"New Engl J Med"},{"key":"CR89","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00019053-199304060-00003","volume":"4","author":"JL Glennie","year":"1993","unstructured":"GlennieJL, WoloschukDMM, HallKW. High technology drugs for cancer: the decision process for adding to a formulary. Pharmaco Economics 1993; 4: 405?13.","journal-title":"Pharmaco Economics"},{"key":"CR90","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00003495-199549020-00001","volume":"49","author":"J Rhoder","year":"1995","unstructured":"RhoderJ, ThomasG. Nicotine treatment in ulcerative colitis: current status. Drugs 1995; 49: 157?60.","journal-title":"Drugs"}],"container-title":["Pharmacy World and Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00820726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00820726\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00820726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T22:21:37Z","timestamp":1682893297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00820726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,10]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,10]]}},"alternative-id":["BF00820726"],"URL":"https:\/\/doi.org\/10.1007\/bf00820726","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,10]]}}}